Recombinant Human TGF-β3

• Expression system Plant-based recombinant production (non-glycosylated protein)
• Sequence Homo sapiens TGF-β3 (112 aa). Uniprot PI0600.
• Molecular Weight 25.4 kDa (by mass spectrometry)
• Structure Homodimer with disulfide bonds
• Bioactivity Validated in HEK293 cells using a luciferase reporter assay
• Purity > 95% (SDS-PAGE)
• Form Vacuum-dried powder
• Recommended Reconstitution 10 mM citric acid : water (1:1) with 0.2% BSA in PBS
• Endotoxin <0.0005 EU/μg

TGF-β3 plays a key role in TGF-β signaling pathways involved in differentiation, tissue remodeling and wound-healing–related cellular models.

• TGF-β signaling pathway research
• In vitro cell differentiation assays
• Wound healing & fibrosis models
• Functional assays using HEK293 or other responsive cell lines

Additional recombinant growth factors are available to support complementary or alternative cell-culture applications.

t

Bioactivity confirmed using HEK293 cells transfected with a TGF-β responsive luciferase reporter. Exposure to plant-derived TGF-β3 resulted in a clear luminescent response, demonstrating strong biological activity.

• Reconstitute using a 1:1 mixture of 10 mM citric acid in water and PBS containing 0.2% albumin.

• Prepare single-use aliquots and store at –80 or -20 °C. Avoid repeated freeze–thaw cycles.

• Shipped with Gel Pack.
• Store at –20 °C for short- to mid-term use. For long-term, store at –80 °C. Avoid repeated freeze-thaw cycles. Once disolved, aliquot and store at –80 °C.

This product is developed, designed and sold exclusively for Research purposes and in vitro use only (RUO). The product was not tested for use in diagnostics or for drug development, nor is it suitable for administration to humans or animals. For more info, please check its Material Safety Data Sheet available in this website.

What is the primary application of recombinant human TGF-β3 in cell-culture models?

Recombinant human TGF-β3 is primarily used to promote chondrogenesis, the differentiation of mesenchymal stem cells into chondrocytes. This process is essential in cartilage formation and is widely studied in advanced in vitro models related to cartilage and bone research.

Why is TGF-β3 particularly relevant for cartilage and bone-related studies?

TGF-β3 plays a central role in cartilage formation, which provides a structural framework for subsequent bone growth. For this reason, it is frequently applied in bone and cartilage engineering models, especially in systems designed to study tissue development and regeneration under controlled experimental conditions.

Is TGF-β3 commonly used with biomaterials or delivery systems?

Yes. A significant proportion of published studies investigate TGF-β3 in combination with scaffolds, hydrogels or biomaterial-based delivery systems. These approaches enable localized and sustained growth-factor presentation, supporting controlled differentiation and tissue-specific responses in cartilage and bone models.

Does TGF-β3 have applications beyond cartilage engineering?

Beyond cartilage-focused models, TGF-β3 has been studied in organ repair and wound-healing–related experimental systems, particularly due to its role in modulating extracellular matrix deposition and reducing fibrotic responses. These properties make it a valuable tool in advanced in vitro models exploring tissue remodeling processes.

How does TGF-β3 differ from other TGF-beta isoforms in research applications?

Compared to other TGF-beta isoforms, TGF-β3 is often associated with reduced fibrotic signaling and more balanced extracellular matrix remodeling. This characteristic has driven interest in its use within experimental models studying fibrosis prevention, cartilage formation and tissue organization.

What types of research workflows typically include recombinant TGF-β3?

Recombinant human TGF-β3 is commonly incorporated into advanced cell-culture systems, including mesenchymal stem-cell differentiation assays, cartilage engineering models, biomaterial-supported cultures and wound-healing–related in vitro studies, where precise modulation of TGF-beta signaling is required.